Re: BOD Votes Against
Easy Joe. One trick pony hasn't used his cash hoard and profitability to expand to a second platform buy purchasing a young promising company with something showing good results in development. He's a disgrace compared to most Bio tech CEO's over the past three or four years.
He's also not willing to stop selling all the shares he can every time he has a chance to. Look at a CEO like Stephan Bancel from MRNA who has kept 18.5 million shares of his stock through out the stocks run the past year while only selling paltry amounts from time to time and that total share count he holds pretty much never varries.